申请人:Otsuka Pharmaceutical Co., Ltd.
公开号:US04147869A1
公开(公告)日:1979-04-03
3,4-Dihydrocarbostyril derivatives represented by the formula (I) ##STR1## wherein R.sub.1 represents an alkylcarbonyl group, a cycloalkylcarbonyl group, an alkylsulfonyl group, a phenylsulfonyl group, a carbamoyl group or an alkoxycarbonyl group, R.sub.2 and R.sub.3, which may be the same or different, each represents a hydrogen atom, an alkyl group, a phenylalkyl group or a phenoxyalkyl group, or R.sub.2 and R.sub.3 can form, when taken together with the nitrogen atom to which they are attached, a heterocyclic group selected from the group consisting of piperidino, pyrrolidino, morpholino and 1-piperazinyl which may be substituted with a phenyl group or an alkyl group having 1 to 4 carbon atoms, with the proviso that, when the group --NHR.sub.1 is attached to the 8-position of the 3,4-dihydrocarbostyril nucleus in which R.sub.1 represents an alkylcarbonyl group and one of R.sub.2 and R.sub.3 represents a hydrogen atom, then the other group of R.sub.2 and R.sub.3 cannot be an alkyl group, pharmaceutically acceptable acid addition salts thereof, and process for preparing the same.
公式(I)所表示的3,4-二氢咔啉衍生物,其中R.sub.1代表烷基羰基基团、环烷基羰基基团、烷基磺酰基团、苯基磺酰基团、氨基甲酰基团或烷氧羰基基团,R.sub.2和R.sub.3,可能相同也可能不同,每个代表氢原子、烷基、苯基烷基或苯氧基烷基,或者R.sub.2和R.sub.3可以与它们附着的氮原子一起形成一个杂环基团,所述杂环基团选自由哪些由哌啶基、吡咯啉基、吗啉基和1-哌嗪基组成的群体,所述群体可以被苯基或具有1到4个碳原子的烷基取代,但是当--NHR.sub.1基团附着在3,4-二氢咔啉核的8位时,其中R.sub.1代表烷基羰基基团并且R.sub.2和R.sub.3中的一个代表氢原子,则R.sub.2和R.sub.3的另一个基团不能是烷基,其药物可接受的酸盐及其制备方法。